| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 8,609,354
- Publication Date: December 17, 2013
- Appl. No: 13/039856
- Application Filed: March 03, 2011
- Assignees: Carpen, Olli (Espoo, FI), Lintunen, Minnamaija (Turku, FI), Ristamaki, Raija (Turku, FI), Sundstrom, Jari (Turku, FI), Algars, Annika (Kuusisto, FI), Hospital District of Southwest Finland (Turku, FI)
- Claim: 1. A method for detecting and analyzing whether a patient suffering from a cancer is responsive or non-responsive to the treatment with an EGFR inhibitor, the method comprising the steps of: (a) determining in a tissue section from a tumor sample obtained from said patient (i) the expression level of an EGFR protein in said tissue section by immunohistochemistry (IHC), and (ii) the level of EGFR gene copy number or the level of copy number of chromosome 7 by enzymatic metallography, wherein an area of highest expression of EGFR in a tissue section from said tumor sample is determined by IHC based on staining intensity, and using enzymatic metallography, a gene copy number of EGFR gene or chromosome 7 is counted from the cells residing in said area of highest expression in the tumor sample; and (b) selecting said patient for treatment with said EGFR inhibitor, if the tumor sample of said patient displays expression of EGFR protein and an amplified copy number of the EGFR gene or chromosome 7.
- Claim: 2. The method according to claim 1 , wherein the same tissue section from said tumor sample is used in IHC and in enzymatic metallography.
- Claim: 3. The method according to claim 1 , wherein consecutive tissue sections from said tumor sample are used in IHC and in enzymatic metallography.
- Claim: 4. The method according to claim 1 , wherein the level of EGFR gene copy number or the level of copy number of chromosome 7 is determined as ratio of the number of EGFR genes or chromosome 7 per nucleus.
- Claim: 5. The method according to claim 1 , wherein said enzymatic metallography is silver in situ hybridization (SISH) analysis.
- Claim: 6. The method according to claim 1 , wherein the patient is selected for the treatment with the EGFR inhibitor, if the level of EGFR gene copy number or the level of copy number of chromosome 7 is statistically similar to or greater than the threshold level of EGFR gene copy number or level of copy number of chromosome 7 that has been correlated with response to the treatment with the EGFR inhibitor.
- Claim: 7. The method according to claim 1 , wherein the patient is not selected for the treatment with the EGFR inhibitor, if the level of EGFR gene copy number or the level of copy number of chromosome 7 is statistically less than the threshold level of EGFR gene copy number or level of copy number of chromosome 7 that has been correlated with response to the treatment with the EGFR inhibitor.
- Claim: 8. The method according to claim 4 or 6 , wherein the patient is selected for the treatment with the EGFR inhibitor, if the level of EGFR gene copy number is ≧4.0 or the level of copy number of chromosome 7 in nucleus is ≧4.5.
- Claim: 9. The method according to claim 1 , wherein said cancer is colorectal cancer, lung cancer, head and neck cancer, or glioma.
- Claim: 10. The method according to claim 1 , wherein IHC is performed with an anti-EGFR antibody.
- Claim: 11. The method according to claim 10 , wherein said antibody binds to an intracellular domain of the EGFR.
- Claim: 12. The method according to claim 10 , wherein said antibody is clone 5B7 or 3C6.
- Claim: 13. The method according to claim 1 , wherein said EGFR inhibitor is an antibody or a kinase inhibitor.
- Claim: 14. The method according to claim 13 , wherein said antibody is cetuximab (mAb c225), matuzumab (mAb h425) or panitumumab (mAb ABX).
- Claim: 15. The method according to claim 13 , wherein said kinase inhibitor is erlotinib or gefitinib.
- Claim: 16. The method according claim 1 further comprising the step of determining the presence or absence of KRAS mutation in said tumor sample.
- Claim: 17. The method according claim 1 further comprising the step of determining the presence of absence of a mutated EGFR gene or EGFR protein in said tumor sample.
- Claim: 18. The method according claim 1 , wherein said tissue section is prepared on a microscope slide.
- Claim: 19. The method according claim 1 , wherein said tissue section is ≦5 μm thick.
- Claim: 20. The method according claim 1 , wherein steps (i) and (ii) are performed with an automated processing apparatus.
- Claim: 21. The method according to claim 1 , wherein said enzymatic metallography is silver in situ hybridization (SISH) analysis and wherein said cancer is colorectal cancer.
- Claim: 22. The method according to claim 1 , wherein the level of staining is determined based on membraneous, cytoplasmic and/or a combination of cytoplasmic and membraneous staining of the cells in a tumor sample.
- Claim: 23. A method of treating a patient suffering from a cancer comprising the steps of obtaining a tumor sample from said patient, analyzing said sample by the method according to claim 1 and administering an EGFR inhibitor to said patient, if said patient was selected for treatment with said EGFR inhibitor.
- Current U.S. Class: 435/723
- Patent References Cited: 2008/0090233 April 2008 Garcia et al. ; 2009/0017050 January 2009 Powell et al. ; 2009/0269344 October 2009 Siena et al. ; WO 00/20641 April 2000 ; WO 2007/133516 November 2007 ; WO 2010/022332 February 2010
- Other References: Gaiser et al (Modern Pathology, published online Jun. 12, 2009; 22:1263-1271, IDS). cited by examiner ; Moroni et al (Lancet Oncology 2005; 6:279-286). cited by examiner ; Gaiser et al., “Comparison of automated silver enhanced in situ hybridization and fluorescense in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas,” Modern Pathology, vol. 22, pp. 1263-1271, 2009. cited by applicant ; Hanawa et al., “EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus,”Int. J. Cancer, vol. 118, pp. 1173-1180, 2006. cited by applicant ; Hemmings et al., “Immunohistochemical expression of EGFR in colorectal carcinoma correlates with hight but not low gene amplification, as demonstrated by CISH,” Pathology, vol. 41, No. 4, pp. 356-360, Jun. 2009. cited by applicant ; Search Report issued Sep. 2, 2010, in Finnish Patent Application No. 20105210. cited by applicant ; Miyanaga et al., “Amplification of the epidermal growth factor receptor gene in glioblastoma: An analysis of the relationship between genotype and phenotype by CISH method,” Neuropathology, vol. 28, pp. 116-126, 2008. cited by applicant ; Sholl et al., “Lung Adenocarcinoma with EGFR Amplification has Distinct Clinicopathologic and Molecular Features in Never-Smokers,” Cancer Res., vol. 69, No. 21, pp. 8341-8348, Nov. 1, 2009. cited by applicant ; Al-Kuraya et al., “HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer”, J Clin Pathol, Jul. 2007 (published online Aug. 2, 2006), vol. 60, pp. 768-772. cited by applicant ; Al-Kuraya et al., “Prognostic relevance of gene amplifications and coamplifications in breast cancer”, Cancer Res, Dec. 1, 2004, vol. 64, pp. 8534-8540. cited by applicant ; Alvarez et al., “Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification”, Modern Pathology, Jul. 2006 (published online Apr. 28, 2006), vol. 19, pp. 942-949. cited by applicant ; Amann et al., “Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer”, Cancer Res, Jan. 1, 2005, vol. 65, No. 1, pp. 226-235. cited by applicant ; Awaya et al., “Gene amplifications and protein expression of EGFR and HER2 by chromogenic in situ hybridization and immunohistochemistry in atypical andenomatous hyperplasia and adenocarcinoma of the lung”, J Clin Pathol, 2005, vol. 58, pp. 1076-1080. cited by applicant ; Balko et al., “Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors”, BMC Genomics, Nov. 10, 2006, vol. 7, No. 289, 14 pages. cited by applicant ; Bengala et al., “EGFR gene copy number, KRAS and BRAF status, PTEN and AKT factor analysis in patients with metastatic colon cancer treated with anti-EGFR monoclonal antibodies ± chemotherapy”, Journal of Clinical Oncology, 2009, vol. 27, No. 15S, e15055, 1 page abstract only. cited by applicant ; Bengala et al., “Epidermal growth factor receprot gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radication therapy in locally advanced rectal cancer”, Annals of Oncology, Mar. 2009 (published online Dec. 18, 2008), vol. 20, No. 3, pp. 469-474. cited by applicant ; Bhargava et al., “EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations”, Mod Pathol, 2005 (published online May 13, 2005), vol. 18, pp. 1027-1033. cited by applicant ; Bonomi et al., “Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors”, Clin Cancer Res, Aug. 1, 2007, vol. 13, 15 Supplemental, pp. 4606S-4612S. cited by applicant ; Bozzetti et al., “Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspitates from distant metastatic sites”, Journal of Thoracic Oncology, Jan. 2008, vol. 3, No. 1, pp. 18-22. cited by applicant ; Braut et al., “Epidermal growth factor receptor protein expression and gene amplification in normal, hyperplastic, and canceruos glottic tissue: immunohistochemical and fluorescent in situ hybridization study on tissue microarrays”, Croat Med J, 2009, vol. 50, No. 4, pp. 370-379. cited by applicant ; Buckley et al., “Epidermal growth factor receptor expression and gene copy number in conventional heptocellular carcinoma”, Am J Clin Pathol, 2008, vol. 129, pp. 245-251. cited by applicant ; Cappuzzo et al., “EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)”, Journal of Thoracic Oncology, May 2007, vol. 2, No. 5, pp. 423-429. cited by applicant ; Cappuzzo et al., “EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients”, Annals of Oncology, Apr. 2008 (published online Dec. 31, 2007), vol. 19, No. 4, pp. 717-723. cited by applicant ; Cappuzzo, “EGFR FISH versus mutation: different tests, different end-points”, Lung Cancer, 2008, vol. 60, pp. 160-165. cited by applicant ; Carlson et al., “Epidermal growth factor receptor genomic variation in NSCLC patients recieving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis”, J Cancer Res Clin Oncol, 2009, (published online May 9, 2009), vol. 135, pp. 1483-1493. cited by applicant ; Cascinu et al., “A combination of gefitinib and FOLFOX-4 as first-line treatment in advances colorectal cancer patients. A GISCAD multicentre phase II study . . . ”, British Journal of Cancer, 2008 (published online Dec. 4, 2007), vol. 98, No. 1, pp. 71-76. cited by applicant ; Casorzo et al., “Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer”, Diagnostic Pathology, Nov. 4, 2009, vol. 4, No. 36, 8 pages. cited by applicant ; Chang et al., “Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients”, Lung Cancer, 2008, vol. 61, pp. 328-339. cited by applicant ; Chiang et al., “Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas”, Oral Oncology, 2008 (published online Apr. 30, 2007), vol. 44, pp. 270-276. cited by applicant ; Cho et al., “Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study”, J Korean Med Sci, 2008, vol. 23, No. 6, pp. 1053-1061. cited by applicant ; Chung et al., “Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry”, Journal of Clinical Oncology, Mar. 20, 2005, vol. 23, No. 9, pp. 1803-1810. cited by applicant ; Chung et al., “Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas”, Journal of Clinical Oncology, Sep. 1, 2006, vol. 24, No. 25, pp. 4170-4176. cited by applicant ; Dacic et al., “Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma”, Am J Clin Pathol, Jun. 2006, vol. 125, pp. 860-865. cited by applicant ; Dahabreh et al., “Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer”, Clinical Cancer Research. Jan. 1, 2010 (published online Dec. 22, 2009), vol. 16, No. 1, pp. 291-303. cited by applicant ; Dancer et al., “Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization”, Oncology Reports, 2007, vol. 18, pp. 151-155. cited by applicant ; Daniele et al., “Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis . . . ”, Molecular Cancer Therapeutics, Apr. 2007, vol. 6, No. 4, pp. 1223-1229. cited by applicant ; Dobashi et al., “Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules”, Modern Pathology, 2004 (published online Jul. 9, 2004), vol. 17, pp. 1497-1505. cited by applicant ; Dziadziuszko et al., “Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy”, Annals of Oncology, Mar. 2007 (published online Nov. 2, 2006), vol. 18, No. 3, pp. 447-452. cited by applicant ; Dziadziuszko et al., “Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence . . . ?”, Clinical Cancer Research, Jul. 15, 2006, vol. 12, Supplemental 14, pp. 4409s-4415s. cited by applicant ; El-Zammar et al., “comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features”, Diagn Mol Pathol, Sep. 2009, vol. 18, No. 3, pp. 133-137. cited by applicant ; Endo et al., “Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy”, Oncology Reports, 2006, vol. 16, pp. 533-541. cited by applicant ; Fischer et al., “Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH)”, Diagn Mol Pathol, Dec. 2008, vol. 17, No. 4, pp. 227-230. . cited by applicant ; Franchi et al., “Epidermal growth factor receptor expression and gene copy number in sinonasal intestinal type adenocarcinoma”, Oral Oncology, Sep. 2009 (published online Feb. 11, 2009), vol. 45, pp. 835-838. cited by applicant ; Freeman et al., “Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors”, Cancer, Sep. 15, 2008 (published online Aug. 14, 2008), vol. 113, No. 6, pp. 1453-1461. cited by applicant ; Gallegos Ruiz et al., “Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization”, Histopathology, 2007, vol. 51, pp. 631-637. cited by applicant ; Gazdar, “Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors”, Oncogene, Aug. 2009, vol. 28, Supplemental 1, pp. S24-S31 (NIH Public Access Author Manuscript, 14 pages). cited by applicant ; Gevorgyan et al., “Epidermal Growth Factor Receptor (EGFr) status detection in correlation to objective response on cetuximab-based therapy in patients (pts) with advanced colorectal cancer (ACC)”, Journal of Clinical Oncology, 2007, vol. 25, No. 18S, 21070, Abstract, 1 page. cited by applicant ; Goncalves et al., “A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment”, BMC Cancer, Jun. 10, 2008, vol. 8, No. 169, 11 pages. cited by applicant ; Hamilton, “Targeted therapy of cancer: new roles for pathologists in colorectal cancer”, Modern Pathology, 2008, vol. 21, pp. S23-S30. cited by applicant ; Han et al., “Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation”, Clinical Cancer Research, Apr. 15, 2006, vol. 12, No. 8, pp. 2538-2544. cited by applicant ; Heinemann et al., “Clinical relevance of epidermal growth factor receptor- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR”, Cancer Treatment Reviews, 2009, vol. 35, pp. 262-271. cited by applicant ; Helfrich et al., “Antitumor activity of the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number . . . ”, Clinical Cancer Research, Dec. 1, 2006, vol. 12, No. 23, pp. 7117-7125. cited by applicant ; Hirsch et al., “Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer”, Current Opinion in Oncology, 2005, vol. 17, pp. 118-122. cited by applicant ; Hirsch et al., “Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib”, Annals of Oncology, Apr. 2007 (published online Feb. 22, 2007), vol. 18, No. 4, pp. 752-760. cited by applicant ; Hirsch et al., “Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis”, Journal of Clinical Oncology, Oct. 15, 2003, vol. 21, No. 20, pp. 3798-3807. cited by applicant ; Hirsch et al., “First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay”, Journal of Thoracic Oncology, Jun. 2008, vol. 3, No. 6, Supplemental 2, pp. S138-S142. cited by applicant ; Hirsch et al., “Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer”, Clinical Cancer Research, Oct. 1, 2008, vol. 14, No. 19, pp. 6317-6323. cited by applicant ; Hirsch et al., “Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy”, Journal of Clinical Oncology, Jul. 10, 2008, vol. 26, No. 20, pp. 3351-3357. cited by applicant ; Hirsch et al., “Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar . . . ”, Journal of Clinical Oncology, Oct. 1, 2005, vol. 23, No. 28, pp. 6838-6845. cited by applicant ; Hirsch et al., “Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer”, Journal of Clinical Oncology, Nov. 1, 2006, vol. 24, No. 31, pp. 5034-5042. cited by applicant ; Hirsch et al., “Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer”, Oncogene, 2009, vol. 28, pp. S32-S37. cited by applicant ; Hodgson et al., “Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts”, Neuro-Oncology, Oct. 2009 (published online Jan. 12, 2009), vol. 11, pp. 477-487. cited by applicant ; Hoff et al., “Visualization of FISH Probes by dual-color chromogenic in situ hybridization”, American Journal of Clinical Pathology, 2010 , vol. 133, pp. 205-211. cited by applicant ; Italiano et al., “Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number”, Annals of Surgical Oncology, 2008 (published online Nov. 7, 2007), vol. 15, No. 2, pp. 649-654. cited by applicant ; Italiano et al., “Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors”, Annals of Oncology, Jun. 2006 (published online Mar. 8, 2006), vol. 17, No. 6, pp. 981-985. cited by applicant ; Italiano et al., “EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy”, Int J Cancer, 2009 (published online Jun. 2, 2009), vol. 125, pp. 2479-2482. cited by applicant ; Järvelä et al., “Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival”, Neuropathology and Applied Neurobiology, 2006, vol. 32, pp. 441-450. cited by applicant ; Jeon et al., “Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer”, Lung Cancer, 2006 vol. 54, pp. 387-398. cited by applicant ; Jimeno et al., “Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer”, Cancer Research, Apr. 15, 2008, vol. 68, No. 8, pp. 2841-2849. cited by applicant ; John et al., “Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors”, Oncogene, 2009, vol. 28, pp. S14-S23. cited by applicant ; Kalish et al., “Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines”, Clinical Cancer Research, Nov. 15, 2004, vol. 10, pp. 7764-7774. cited by applicant ; Kanteti et al., “MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance”, J Environ Pathol Toxicol Oncol, 2009, vol. 28, No. 2, pp. 89-98 (NIH Public Access Author Manuscript, 14 pages). cited by applicant ; Kersting et al., “Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma”, Laboratory Investigation, 2004 (published online Mar. 15, 2004), vol. 84, pp. 582-587. cited by applicant ; Kersting et al., “Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas”, J Clin Pathol, 2006, vol. 59, pp. 585-590. cited by applicant ; Khambata-Ford et al., “Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced . . . ”, Journal of Clinical Oncology, Feb. 20, 2010 (published online Jan. 25, 2010), vol. 28, No. 6, pp. 918-927. cited by applicant ; Kim et al., “EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number”, Histopathology, 2008, vol. 52, pp. 738-746. cited by applicant ; Kim et al., “High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer”, British Journal of Cancer, 2008 (published online Feb. 19, 2008), vol. 98, No. 6, pp. 1118-1124. cited by applicant ; Kimura et al., “A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization . . . ”, Virchows Arch, 2004, vol. 445, pp. 255-262. cited by applicant ; Kirkegaard et al., “Amplified in breast cancer 1 in human epidermal growth factor receptor—positive tumors of tamoxifen-treated breast cancer patients”, Clinical Cancer Research, Mar. 1, 2007, vol. 13, No. 5, pp. 1405-1411. cited by applicant ; Koynova et al., “Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx”, J Cancer Res Clin Oncol, 2005 (published online Dec. 8, 2004), vol. 131, pp. 199-203. cited by applicant ; Kubo et al., “MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors”, Int J Cancer, Apr. 15, 2009, vol. 124, No. 8, pp. 1778-1784 (NIH public access author manuscript, 17 pages). cited by applicant ; Lambros et al., “Chromogenic and fluorescent in situ hybridization in breast cancer”, Human Pathology, 2007, vol. 38, pp. 1105-1122. cited by applicant ; Laurent-Puig et al., “Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer”, Journal of Clinical Oncology, Dec. 10, 2009 (published online Nov. 2, 2009), vol. 27, No. 35, pp. 5924-5930. cited by applicant ; Le Tourneau et al., “Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents”, Drug Resistance Updates, 2008, vol. 11, pp. 99-109. cited by applicant ; Lee et al., “Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors”, Appl Immunohistochem Mol Morphol, Jan. 2010, vol. 18, No. 1, pp. 69-74. cited by applicant ; Lee et al., “Epidermal growth factor receptor status in anaplastic thyroid carcinoma”, J Clin Pathol, 2007 (published online Nov. 1, 2006), vol. 60, pp. 881-884. cited by applicant ; Lee et al., “Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma”, Cancer, Apr. 15, 2007 (published online Mar. 12, 2007), vol. 109, No. 8, pp. 1561-1569. cited by applicant ; Lee et al., “Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry . . . ”, Lung Cancer, 2010, vol. 68, pp. 375-382. cited by applicant ; Li et al., “EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression”, Journal of Molecular Diagnostics, May 2008, vol. 10, No. 3, pp. 242-248. cited by applicant ; Liang et al., “Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients”, BMC Cancer, Dec. 6, 2008, vol. 8, No. 363, 12 pages. cited by applicant ; Lievre et al., “Facteurs prédictifs de réponse aux traitements anti-REGF dans le cancer colorectal”, Bull Cancer, Jan. 2008, vol. 95, No. 1, pp. 133-140. cited by applicant ; Lopes et al., “EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases”, Modern Pathology, 2007 (published online Jul. 20, 2007), vol. 20, pp. 990-994. cited by applicant ; Lopez-Gines et al., “New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile”, Modern Pathology, 2010 (published online Mar. 19, 2010), vol. 23, pp. 856-865. cited by applicant ; Macarenco et al., “Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study”, Modern Pathology, 2008 (published online Jun. 27, 2008), vol. 21, pp. 1168-1175. cited by applicant ; Mancuso et al., “EGFR, DCC, and K-RAS mutations as predictive factors for cetuximab sensitivity in metastatic colorectal cancer (mCRC)”, Journal of Clinical Oncology, 2008, vol. 26, No. 15S, 4128, Abstract 1 page. cited by applicant ; Marks et al., “Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis”, The Prostate, 2008 (published online Apr. 11, 2008), vol. 68, pp. 919-923. cited by applicant ; Marquez et al., “Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy”, Diagn Mol Pathol, Mar. 2004, vol. 13, No. 1, pp. 1-8. cited by applicant ; Meriggi et al., “Anti-EGFR therapy in colorectal cancer: how to choose the right patient”, Current Drug Targets, Oct. 2009, vol. 10, No. 10, pp. 1033-1040. cited by applicant ; Merlino et al., “Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line”, The Journal of Clinical Investigation, Inc., Mar. 1985, vol. 75, pp. 1077-1079. cited by applicant ; Milano et al., “Epidermal growth factor receptor (EGFR) status and K-RAS mutations in colorectal cancer”, Annals of Oncology, Dec. 2008 (published online Jul. 15, 2008), vol. 19, No. 12, pp. 2033-2038. cited by applicant ; Moch et al., “EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization”, Journal of Pathology, 1998, vol. 184, pp. 424-429. cited by applicant ; Modrek et al., “oncogenic activating mutations are associated with local copy gain”, Molecular Cancer Research, Aug. 2009, vol. 7, No. 8, pp. 1244-1252. cited by applicant ; Mrhalova et al., “Epidermal growth factor receptor—its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas”, Neoplasma, 2005, vol. 52, No. 4, pp. 338-343. cited by applicant ; Neyns et al., “Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma”, Annals of Oncology, Sep. 2009 (published online Jun. 2, 2009), vol. 2, No. 9, pp. 1596-1603. cited by applicant ; Okuda et al., “Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma”, J Cancer Res Clin Oncol, 2008 (published online Apr. 8, 2008), vol. 134, pp. 1105-1111. cited by applicant ; Ooi et al., “Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma”, Anticancer Res, 2009, vol. 29, pp. 19-26. cited by applicant ; Park et al., “EGFR gene and protein expression in breast cancers”, EJSO the Journal of Cancer Surgery, 2007 (published online Mar. 19, 2007), vol. 33, pp. 956-960. cited by applicant ; Park et al., “EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology”, Lung Cancer, 2009, vol. 64, pp. 179-186 cited by applicant ; Peled et al., “Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer”, Therapeutic Advances in Medical Oncology, Nov. 2009, vol. 1, No. 3, pp. 137-144. cited by applicant ; Pennell et al., “Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors”, Biomarkers Med, 2007, vol. 1, No. 1, pp. 203-207. cited by applicant ; Personeni et al., “Clinical usefulness of Egfr gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study”, Clin Cancer Res, Sep. 15, 2008, vol. 14, No. 18, pp. 5869-5876. cited by applicant ; Personeni, “Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: does intratumoral heterogeneity matter?”, Journal of Clinical Oncology, Dec. 1, 2006, vol. 24, No. 34, pp. 5465. cited by applicant ; Pinter et al., “Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry”, Journal of Molecular Diagnostics, Mar. 2008, vol. 10, No. 2, pp. 160-168. cited by applicant ; Pugh et al., “Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients”, BMC Cancer, Jul. 13, 2007, vol. 7, No. 128, 12 pages. cited by applicant ; Rakosy et al., “EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis”, Int J Cancer, 2007, vol. 121, pp. 1729-1737. cited by applicant ; Reis-Filho et al., “Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis”, Breast Cancer Research, 2005, vol. 7, No. 6, pp. R1028-R1035. cited by applicant ; Rosell et al., “Usefulness of predictive tests for cancer treatment”, Bull Cancer, 2006, vol. 93, No. 8, pp. E101-E108. cited by applicant ; Rydén et al., “Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial . . . ”, Breast Cancer Res Treat, 2010 (published online Feb. 5, 2010), vol. 120, pp. 491-498. cited by applicant ; Ryott et al., “EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma”, European Journal of Cancer, 2009 (published online Mar. 28, 2009), vol. 45, pp. 1700-1708. cited by applicant ; Sakurada et al., “Predictive biomarkers for EGFR therapy”, IDrugs, Jan. 2009, vol. 12, No. 1, pp. 34-38. cited by applicant ; Sartore-Bianchi et al., “Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer”, Targ Oncol, 2010 (published online Apr. 11, 2010), vol. 5, pp. 19-28. cited by applicant ; Sartore-Bianchi, “Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab”, Journal of Clinical Oncology, Aug. 1, 2007, vol. 25, No. 22, pp. 3238-3245. cited by applicant ; Sauer et al., “Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?”, Histopathology, 2005, vol. 47, pp. 560-564. cited by applicant ; Sauer et al., “EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization”, Diagnostic Cytopathology, 2005, vol. 33, No. 4, pp. 228-232. cited by applicant ; Sauter et al., “Patterns of epidermal growth factor receptor amplification in malignant gliomas”, Am J Pathol, Apr. 1996, vol. 148, No. 4, pp. 1047-1053. cited by applicant ; Savic et al., “Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers”, British Journal of Cancer, 2008 (published online Dec. 18, 2007), vol. 98, No. 1, pp. 154-160. cited by applicant ; Scartozzi et al., “Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic . . . ”, BMC Cancer, Aug. 27, 2009, vol. 9, No. 303, 8 pages. cited by applicant ; Schlomm et al., “Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer”, Clinical Cancer Research, Nov. 15, 2007, vol. 13, No. 22, pp. 6579-6584. cited by applicant ; Schneider et al., “Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study”, Journal of Thoracic Oncology, Dec. 2008, vol. 3, No. 12, pp. 1446-1453. cited by applicant ; Shafizadeh et al., “Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder”, Human Pathology, 2010, vol. 41, pp. 485-492. cited by applicant ; Sheu et al., “Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma”, Cancer Research, Mar. 15, 2009, vol. 69, No. 6, pp. 2568-2576 (published online Mar. 10, 2009). cited by applicant ; Sholl et al., “Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma”, Modern Pathology, 2007 (published online Aug. 3, 2007), vol. 20, pp. 1028-1035. cited by applicant ; Skacel et al., “Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason . . . ”, Human Pathology, Dec. 2001, vol. 32, No. 12, pp. 1392-1397. cited by applicant ; Sone et al., “Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer”, Cancer, 2007 (published online Mar. 26, 2007), vol. 109, No. 9, pp. 1836-1844. cited by applicant ; Spindler et al., “Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods”, International Journal of Oncology, 2006, vol. 29, pp. 1159-1165. cited by applicant ; Stadlmann et al., “Epithelial growth factor receptor status in primary and recurrent ovarian cancer”, Modern Pathology, 2006, vol. 19, pp. 607-610. cited by applicant ; Tang et al., “Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas”, Cancer Prevention Research, Aug. 2008, vol. 1, No. 3, pp. 192-200. cited by applicant ; Taron et al., “Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas”, Clinical Cancer Research, Aug. 15, 2005, vol. 11, No. 16, pp. 5878-5885. cited by applicant ; Tatematsu et al., “Epidermal growth factor receptor mutations in small cell lung cancer”, Clinical Cancer Research, Oct. 1, 2008, vol. 14, No. 19, pp. 6092-6096. cited by applicant ; Temam et al., “Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer”, Journal of Clinical Oncology, Jun. 1, 2007, vol. 25, No. 16, pp. 2164-2170. cited by applicant ; Tiseo et al., “Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers”, Lung Cancer, 2010, vol. 67, pp. 355-360. cited by applicant ; Toschi et al., “Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors”, The Oncologist, 2007, vol. 12, pp. 211-220. cited by applicant ; Toth et al., “Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma”, Pathol Oncol Res, 2009 (published online Aug. 28, 2008), vol. 15, pp. 225-229. cited by applicant ; Toyama et al., “Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers”, BMC Cancer, Oct. 25, 2008, vol. 8, No. 309, 12 pages. cited by applicant ; Tsiambas et al., “Chromogenic in situ hybridization analysis of EGFR gene copies in colon adenocarcinoma based on intra-operative imprints and tissue microarrays”, J Gastrointestin Liver Dis, Sep. 2009, vol. 18, No. 3, pp. 293-298. cited by applicant ; Tsiambas et al., “Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays”, Cancer Informatics, 2007, vol. 3, pp. 275-284. cited by applicant ; Udart et al., “Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases”, Neoplasia, 2001, vol. 3, No. 3, pp. 245-254. cited by applicant ; Uramoto et al., “Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?”, British Journal of Cancer, 2007 (published online Feb. 27, 2007), vol. 96, No. 6, pp. 857-863. cited by applicant ; Varella-Garcia et al., “EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and assoc. with EGFR and KRAS . . . ”, J Thorac Oncol, 2009, vol. 4, pp. 318-325 (NIH public access author manuscript 16 pages). cited by applicant ; Varella-Garcia et al., “EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer”, J Clin Pathol, 2009, vol. 62, pp. 970-977. cited by applicant ; Varella-Garcia, “Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay”, Diagnostic Pathology, Aug. 15, 2006, vol. 1, No. 19, 10 pages. cited by applicant ; Vermeij et al., “Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers”, BMC Cancer, Jan. 8, 2008, vol. 8, No. 3, 9 pages. cited by applicant ; Viana-Pereira et al., “Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas”, Anticancer Research, 2008, vol. 28, pp. 913-920. cited by applicant ; Vidal et al., “Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib”, Head Neck, Aug. 2009, vol. 31, No. 8, pp. 1006-1012 (NIH public access author manuscript, 10 pages). cited by applicant ; Wang et al., “Epidermal growth factor protein expression and gene amplification in small call carcinoma of the urinary bladder”, Clinical Cancer Research, Feb. 1, 2007, vol. 13, No. 3, pp. 953-957. cited by applicant ; Wang et al., “Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma”, Modern Pathology, Jan. 2009 (published online Jul. 25, 2008), vol. 22, pp. 7-12. cited by applicant ; Wei et al., “EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens”, Modern Pathology, 2007 (published online Jul. 20, 2007), vol. 20, pp. 905-913. cited by applicant ; Williams et al., “Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance”, Clinical Cancer Research, Apr. 15, 2010 (published online Apr. 14, 2010), vol. 16, No. 8, pp. 2266-2274. cited by applicant ; Wilmore-Payne et al., “Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number . . . ”, Human Pathology, 2006, vol. 37, pp. 755-763. cited by applicant ; Wong et al., “Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification”, Proc Natl Acad Sci USA, Oct. 1987, vol. 84, pp. 6899-6903. cited by applicant ; Yamatodani et al., “Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines”, J Cancer Res Clin Oncol, 2009 (published online Sep. 2008), vol. 135, pp. 395-402. cited by applicant ; Yan et al., “Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development”, Biotechniques, Oct. 2005, vol. 39, pp. 565-568. cited by applicant ; Yatabe et al., “Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer”, Cancer Research, Apr. 1, 2008, vol. 68, No. 7, pp. 2106-2111. cited by applicant ; Yoo et al., “Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study”, Lung Cancer, 2010, vol. 67, pp. 301-305. cited by applicant ; Zakowski et al., “Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib”, Arch Pathol Lab Med, Mar. 2009, vol. 133, pp. 470-477. cited by applicant ; Zhu et al., “Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21”, Journal of Clinical Oncology, Sep. 10, 2008 (published online Jul. 14, 2008), vol. 26, No. 26, pp. 4268-4275. cited by applicant ; Zlobec et al., “Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens”, Lung Cancer, 2010, vol. 68, pp. 192-197. cited by applicant
- Primary Examiner: Goddard, Laura B
- Attorney, Agent or Firm: Birch, Stewart, Kolasch & Birch, LLP
|
